Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib in HR+/HER2- Advanced Breast Cancer (CAPIcorn)
NCT07281833Phase 3Recruiting
- Sponsor
- Women's Cancer Study Group
- Start
- Nov 2025
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of capivasertib in breast cancer, sponsored by Women's Cancer Study Group. Started Nov 2025; status: recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07281833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281833.